Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-07-24
2007-07-24
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S174100, C424S141100, C424S142100, C424S178100, C424S009200
Reexamination Certificate
active
08905293
ABSTRACT:
The present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an immunoglobulin or Ig fusion protein molecule to the subject, the immunoglobulin molecule having a variable region and a constant region, the immunoglobulin molecule being modified prior to administration by inactivation of at least a portion of the constant region.
REFERENCES:
patent: 5338669 (1994-08-01), Gillies
patent: 5648260 (1997-07-01), Winter et al.
patent: 5714350 (1998-02-01), Co et al.
patent: 5728821 (1998-03-01), Yelton et al.
patent: 5792456 (1998-08-01), Yelton et al.
patent: 5872222 (1999-02-01), Chang
patent: 6020145 (2000-02-01), Hellstrom et al.
patent: 6180377 (2001-01-01), Morgan et al.
patent: 2006/0134709 (2006-06-01), Stavenhagen et al.
patent: 0 699 756 (1996-03-01), None
patent: 0699756 (1996-03-01), None
patent: 03128330 (1991-05-01), None
patent: WO 91/00295 (1991-01-01), None
patent: WO 93/02702 (1993-02-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 94/29451 (1994-12-01), None
Eghtedarzadeh-Kondri et al. BioTechniques 23: 830-834, 1997.
Comereski et al. Toxicol. Pathol. 22: 473-488, 1994.
Muroi et al. Blood 79: 713-719, abstract, 1992.
Goldenberg DM. Ca 44: 43(22), 1994.
Dorai et al. Hybridoma 10: 211-217, abstract, 1991.
Lo et al. Human Antibodies Hybridoma 3: 123-138, abstract, 1991.
Chiorini et al. Int. J. Cancer 53: 97-103, abstract, 1993.
Calvo et al. Cancer Biother. 8: 95-109, abstract, 1993.
Chiorini et al. Cancer Res. 55: 5957s-5967s, abstract, 1995.
Robinson et al. Human Antibodies Hybridoma 2: 84-93, abstract, 1991.
Siegall et al. Bioconjugate Chem. 3: 302-307, 1992.
Slavin-Chiorini et al. Cancer Res. 55: 5957s-5967s, Dec. 1, 1995.
Carlin et al. J. Nucl. Med. 44: 1827-1838, 2003 (abstract)
Cook et al. Cancer Biother. Radiopharm. 11: 415-422, 1996 (abstract).
D. Yelton, et al., “Mutant Monoclonal Antibodies With Alterations in Biological Functions,”J. Exp. Medicine, vol. 56, pp. 1131-1148, Oct. 1982 (Exhibit 3).
Mueller, et al., “Serum Half-Life and Tumor Localization of a Chimeric Antibody Delected of the CH2 Domain and Directed Against the Disialoganglioside GD2,”P.N.A.S., vol. 87, pp. 5702-5705, Aug. 1990 (Exhibit 4).
H. Garrigues, et al., Detection of a Human Melanoma-Associated Antigen, p97, in Histological Sections of Primary Human Melanomas,Int. J. Cancer, vol. 29, pp. 511-515, 1982 (Exhibit 5).
Alexander R. Duncan, et al., “The Binding Site for Clq on IgG”Nature, vol. 332, pp. 738-740, Apr. 1988 (Exhibit 6).
Mi-Hua Tao, et al., “Structural Features of Human Immunoglobulin G That Determine Isotype-Specific Differences in Complement Activation”J. Exp. Med., vol. 178, No. 2, pp. 661-667, Aug. 1993 (Exhibit 7).
Yuanyuan. Xu, et al., “Residue at Position 331 in the IgG1 and IgG4 Domains Contributes to Their Differential Ability to Bind and Activate Complement”J. Biol. Chem., vol. 269, No. 5, pp. 3469-3474, Feb. 1994 (Exhibit 8).
A. Morgan, et al., “The N-Terminal End of the CH2 Domain of Chimeric Human IgG1 Anti-HLA-DR is Necessary for Clq, FcγRI and FcγRIII Binding”Immunology, vol. 86, pp. 319-324, 1995 (Exhibit 9).
Mae Joanne Rosok, et al. “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,”J. Biol. Chem., vol. 271, No. 37, pp. 22611-22618, Sep. 1996 (Exhibit 10).
Mi-Hua Tao, et al., “the Differential Ability of Human IgG1 and IgG4 to Activate Complement is Determined by the COOH-Terminal Sequence of the CH2 Domain,”J. Exp. Med., vol. 173, pp. 1025-1028, Apr. 1991 (Exhibit 11).
I. Hellström, et al., “Strong Antitumor Activities of IgG3 Antibodies to a Human Melanoma-Associated Ganglioside,”P.N.A.S., vol. 82, pp. 1499-1502, Mar. 1985 (Exhibit 12).
Stephen D. Gillies, et al., “Antigen Binding And Biological Activites of Engineered Mutant Chimeric Antibodies With Human Tumor Specificities,”Hum. Antibod. Hybridomas, vol. 1, No. 1, pp. 47-54, 1990.
George J. Schreiber, et al., “An Unmodified Anticarninoma Antibody, BR96, Localizes to And Inhibits The Outgrowth of Human Tumors in Nude Mice,”Cancer Research, vol. 52, pp. 3262-3266, Jun. 15, 1992.
L. Tan et al., Influence Of The Hinge Region On Complement Activation, Clg Binding, And Segmental Flexibility In Chimeric Human Immunoglobulins,Proceedings of the National Academy of Sciences Of The USA, 1990, vol. 8, No. 1, pp. 162-166.
J. Lund et al., Human FcγRI and FcγRII Interact With Distinct But Overlapping Sites On Human IgG,The Journal Of Immunology, 1991, vol. 147, No. 8, pp. 2657-2662.
T. Michaelson et al., One Disulfide Bond In Front Of The Second Heavy Chain Constant Region Is Necessary And Sufficient For Effector Functions Of Humans IgG3 Without A Genetic Hinge,Proceedings Of The National Academy Of Sciences Of The USA, 1994, vol. 91, No. 20, pp. 9243-9247.
Weiner et al. (1994), Journal of Immunology, “The Role of T Cell Activation in Anti-CD3 x Antitumor Bispecific Antibody Therapy” 152:2385-2392.
Canfield, et al., “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region”, J. Exp. Med., vol. 173, pp. 1483-1491 (1991).
Rosok Mae Joanne
Yelton Dale E.
Bristol--Myers Squibb Company
Devi S.
LandOfFree
Method for inhibiting immunoglobulin-induced toxicity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting immunoglobulin-induced toxicity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting immunoglobulin-induced toxicity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3753495